UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities and Exchange Act of 1934

 

Date of Report:  October 3, 2016

(Date of earliest event reported)

 

Invitae Corporation

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-36847

 

27-1701898

(State or other jurisdiction of

 

(Commission File Number)

 

(I.R.S. employer

incorporation or organization)

 

 

 

identification number)

 

458 Brannan Street, San Francisco, California 94107

(Address of principal executive offices, including zip code)

 

(415) 374-7782
(Registrant’s telephone number, including area code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 8.01                                           Other Events.

 

On October 3, 2016, Invitae Corporation announced that the Centers for Medicare and Medicaid Services (CMS) announced final pricing of $925 per test for genetic testing for hereditary breast cancer- related disorders (e.g. hereditary breast cancer, hereditary ovarian cancer, and hereditary endometrial cancer). The tests are billed under the new current procedure terminology (CPT) code 81432, which became effective on January 1, 2016. CMS had previously announced a temporary payment per test of $622.53. Payments are made by Noridian Healthcare Solutions, CMS’s administrative contractor for California.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated:  October 3, 2016

 

 

INVITAE CORPORATION

 

 

 

 

 

By:

/s/ Lee Bendekgey

 

Name:

Lee Bendekgey

 

Title:

Chief Financial Officer, General Counsel and Secretary

 

3